Mineralys Therapeutics (MLYS) traded up 0.05 % during a 24 hours period ending at 05:18 AM Central Europe on Wednesday 28th. One Mineralys Therapeutics stock can currently be bought for about USD 21.13 on popular exchanges. Current supply of Mineralys Therapeutics stocks is 89.2 mn. Mineralys Therapeutics has a current market capitalization of USD 1.8 bn and approximately USD 16.4 mn worth of Mineralys Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Mineralys Therapeutics has traded -19.78 % down. Simple moving average of last 200 days is at USD 27.25. The highest price of past 52 weeks was recorded at USD 47.65 on 11/12/2025. 52 weeks low was at USD 20.12 on 10/16/2026.

Here is how related stocks have performed in the past 24 hours:

  • Stagwell (STGW) traded down -3.34 % and now trades at USD 8.85. Stagwell has a market capitalisation of USD 2.1 bn. Current price/earnings ratio for Stagwell is 138.98.

  • Erock (EROC) traded up 5.76 % and now trades at USD 9.22. Erock has a market capitalisation of USD 2.2 bn.

  • Recursion (RXRX) traded up 2.7 % and now trades at USD 4.05. Current market capitalisation for Recursion is USD 2.2 bn.

  • Neogenomics (NEO) traded up 0.6 % and now trades at USD 17.27. Neogenomics has a market capitalisation of USD 2.2 bn.

  • Vericel (VCEL) traded up 1.2 % and now trades at USD 43.27. Current market capitalisation for Vericel is USD 2.2 bn. Current price/earnings ratio for Vericel is 90.02.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in developing medications to target diseases caused by excessive aldosterone levels. The company is located in Wayne, United States and operates in the Health Care sector. Their primary focus is on creating aldosterone synthase inhibitors (ASI) for treating uncontrolled hypertension. You can find more information about their work and offerings on their website, www.mineralystx.com , and they are listed on the Nasdaq stock exchange. Their Initial Public Offering (IPO) is scheduled for February 9, 2023.